Adjuvant Immunotherapy for Kidney Cancer — A New Strategy with New Challenges

This editorial reviews updated findings from the KEYNOTE 564 trial, which evaluated adjuvant pembrolizumab following nephrectomy in patients with high risk renal cell carcinoma. The trial demonstrated a significant overall survival benefit, with a 38% reduction in risk of death compared to placebo. The authors discuss implications for clinical practice, overtreatment risks, and future directions in biomarker driven risk stratification and sequencing of immunotherapies.

This editorial reviews updated findings from the KEYNOTE 564 trial, which evaluated adjuvant pembrolizumab following nephrectomy in patients with high risk renal cell carcinoma. The trial demonstrated a significant overall survival benefit, with a 38% reduction in risk of death compared to placebo. The authors discuss implications for clinical practice, overtreatment risks, and future directions in biomarker driven risk stratification and sequencing of immunotherapies.